Most Read Articles
17 Jun 2019
Podcast: Dr Sara Hurvitz highlights that the addition of ribociclib to endocrine therapy improved overall survival in premenopausal women with HR+, HER2- advanced breast cancer, according to the MONALEESA-7 trial.
30 Nov 2018
New drug applications approved by US FDA as of 16 - 30 November 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Roshini Claire Anthony, 2 days ago

A combination of tocilizumab and methotrexate reduced disease activity at 2 years compared with methotrexate plus prednisone in patients with early rheumatoid arthritis (RA), an effect not demonstrated with tocilizumab monotherapy.

14 May 2019
At the recent GLYCEMIC GUARDIANS™ dinner symposium, three eminent speakers spoke on theindispensable role of medical nutrition therapy (MNT) in improving outcomes for patients with type2 diabetes (T2D).

Disparity seen between anticoagulation prescription, guidelines

13 May 2019

Prescribing of prophylactic anticoagulation appears to be inconsistent with current practice guidelines, suggests a recent study. However, there appears to be lower thromboembolic events than recorded in previously published literature.

Of the 130 patients included in the study, 92 (70.8 percent) were prescribed lenalidomide and 38 (29.2 percent) pomalidomide. Nearly half of the patients (n=54; 41.5 percent) had a total risk score of 2. Aspirin 81 mg oral tablet was the most common prescription (n=53; 40.8 percent), followed by no anticoagulation (n=30; 23.1 percent).

A total of 27 patients (20.8 percent) were prescribed anticoagulation in accordance with National Comprehensive Cancer Network guidelines. The most common adverse event was incidence of deep venous thromboembolism (n=4; 3.1 percent), followed by major bleeding (n=1; 0.8 percent). There were no reported incidence of pulmonary embolism, myocardial infarction or stroke.

This retrospective study at an ambulatory oncology clinic evaluated overall adherence to guideline recommendations for anticoagulation therapy with lenalidomide and pomalidomide in multiple myeloma patients. The authors utilized chart reviews from the calendar years 2013–2016.

Prescription of appropriate anticoagulation upon initiation of therapy based on a list of predetermined risk factors was the primary endpoint, while secondary endpoints included incidence of deep venous thromboembolism, pulmonary embolism, myocardial infarction, stroke and major bleeding; initial anticoagulant prescribed; and whether or not anticoagulation was prescribed for another disease state.

“Lenalidomide and pomalidomide are two immunomodulatory medications with the potential to improve outcomes for patients with multiple myeloma; however, a black box warning for venous thromboembolism exists,” the authors said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
17 Jun 2019
Podcast: Dr Sara Hurvitz highlights that the addition of ribociclib to endocrine therapy improved overall survival in premenopausal women with HR+, HER2- advanced breast cancer, according to the MONALEESA-7 trial.
30 Nov 2018
New drug applications approved by US FDA as of 16 - 30 November 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Roshini Claire Anthony, 2 days ago

A combination of tocilizumab and methotrexate reduced disease activity at 2 years compared with methotrexate plus prednisone in patients with early rheumatoid arthritis (RA), an effect not demonstrated with tocilizumab monotherapy.

14 May 2019
At the recent GLYCEMIC GUARDIANS™ dinner symposium, three eminent speakers spoke on theindispensable role of medical nutrition therapy (MNT) in improving outcomes for patients with type2 diabetes (T2D).